Researchers described a peptide-directed, hypoxia-sensitive AAV system designed to enhance tumor-specific delivery in non-small cell lung cancer. The platform uses capsid retargeting plus hypoxia-responsive transcriptional control and RNA interference, compressed into a single AAV9 vector. The work reflects a continued push to overcome delivery barriers in solid tumors by linking viral activation to tumor microenvironment features like hypoxia, aiming to reduce off-target effects while improving intracellular payload expression.